Historically, epidemiological studies have demonstrated an association between circulating levels of serum total cholesterol and cardiovascular risk.
1 Investigation of lipoprotein subfractions pointed to the atherogenic potential for apolipoprotein B-100 (apoB-100)–containing lipoproteins (low-density lipoproteins [LDL], intermediate-density lipoproteins [IDL], and very-low-density lipoproteins [VLDL]), and guidelines have historically focused on LDL-cholesterol (LDL-C). Such a focus was not unreasonable, given that the foundational lipid-modifying therapy is statin based and that statins can cause upregulation of the LDL receptor, clearance of LDL particles, and a reduction in serum LDL-C levels. Indeed, development of additional therapies that further reduce LDL-C and cardiovascular risk, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has given clinicians additional tools that, when used in combination, can reduce LDL-C by approximately 85%.